Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | CNR2 | P34972 | 8/20 | 0.51 |
| ▸ | CASR | P41180 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454530 | 0.91 | DRD2 (0.58) | CNR1DRD2HTR2A | |
| SCHEMBL5454399 | 0.88 | CNR1 (0.58) | CNR1MTNR1AMTNR1BCNR2CASR | |
| SCHEMBL5452635 | 0.87 | CNR1 (0.46) | CNR1MTNR1AMTNR1BEPHX2CNR2 | |
| SCHEMBL5453669 | 0.85 | PRMT5 (0.47) | — | |
| SCHEMBL5463285 | 0.84 | MTNR1A (0.51) | CNR1MTNR1AMTNR1BCNR2CASR | |
| SCHEMBL14530812 | 0.83 | EPHX2 (0.63) | CNR1MTNR1AMTNR1BEPHX2CNR2 | |
| SCHEMBL926546 | 0.81 | CNR1 (0.54) | CNR1MTNR1AMTNR1BEPHX2CNR2 | |
| SCHEMBL5453708 | 0.81 | POLB (0.55) | CNR1CNR2CASRDRD2HTR2A | |
| SCHEMBL5461409 | 0.81 | RAB9A (0.51) | MTNR1AMTNR1BDRD2HTR2A | |
| SCHEMBL5456100 | 0.80 | MEN1 (0.46) | CNR1MTNR1AMTNR1BEPHX2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | CNR1 336/4885MTNR1A 435/4885MTNR1B 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.